JP5410431B2 - イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 - Google Patents
イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 Download PDFInfo
- Publication number
- JP5410431B2 JP5410431B2 JP2010526362A JP2010526362A JP5410431B2 JP 5410431 B2 JP5410431 B2 JP 5410431B2 JP 2010526362 A JP2010526362 A JP 2010526362A JP 2010526362 A JP2010526362 A JP 2010526362A JP 5410431 B2 JP5410431 B2 JP 5410431B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- imidazo
- compound
- thiadiazol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BOXRDDIXJOUZLV-UHFFFAOYSA-N 2h-imidazo[4,5-d]thiadiazole Chemical class N1SC2=NC=NC2=N1 BOXRDDIXJOUZLV-UHFFFAOYSA-N 0.000 title description 10
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 3
- 239000003909 protein kinase inhibitor Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 284
- 125000000217 alkyl group Chemical group 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 71
- 238000006243 chemical reaction Methods 0.000 claims description 63
- 125000005843 halogen group Chemical group 0.000 claims description 63
- 125000001424 substituent group Chemical group 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- 239000001257 hydrogen Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 150000001408 amides Chemical class 0.000 claims description 40
- 150000002148 esters Chemical class 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000042867 PIM family Human genes 0.000 claims description 14
- 108091082273 PIM family Proteins 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 6
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000015768 polyposis Diseases 0.000 claims description 6
- 230000002980 postoperative effect Effects 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 230000036262 stenosis Effects 0.000 claims description 6
- 208000037804 stenosis Diseases 0.000 claims description 6
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 206010062016 Immunosuppression Diseases 0.000 claims description 5
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 229940000425 combination drug Drugs 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 201000004931 neurofibromatosis Diseases 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 4
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 201
- -1 Bad Proteins 0.000 description 134
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 238000005481 NMR spectroscopy Methods 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 46
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 44
- 239000000543 intermediate Substances 0.000 description 42
- 238000004440 column chromatography Methods 0.000 description 36
- 239000000377 silicon dioxide Substances 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- 102000001253 Protein Kinase Human genes 0.000 description 26
- 108060006633 protein kinase Proteins 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 125000002947 alkylene group Chemical group 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 101100297652 Coturnix japonica PIM3 gene Proteins 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 12
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 12
- 108060006706 SRC Proteins 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 125000002950 monocyclic group Chemical group 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- UGXVDUGZIINDML-UHFFFAOYSA-N 1-[3-[2-(2-methylpropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(C(C)=O)=C1 UGXVDUGZIINDML-UHFFFAOYSA-N 0.000 description 4
- HISULRSMUDIKIT-UHFFFAOYSA-N 1-[3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NC4CCCCC4)SC3=NC=2)=C1 HISULRSMUDIKIT-UHFFFAOYSA-N 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- GAIGXSIJEITWDD-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(2-pyridin-2-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 GAIGXSIJEITWDD-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010256 biochemical assay Methods 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RMHWWNHEPKGLEW-UHFFFAOYSA-N 1-[3-[2-(oxan-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 RMHWWNHEPKGLEW-UHFFFAOYSA-N 0.000 description 3
- LCNFEUXOURGYIS-UHFFFAOYSA-N 1-[3-[2-(thiophen-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 LCNFEUXOURGYIS-UHFFFAOYSA-N 0.000 description 3
- JFHCFWOCRFEOAG-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CN=C2SC(Br)=NN21 JFHCFWOCRFEOAG-UHFFFAOYSA-N 0.000 description 3
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- CDMSUMPDCNIYMR-UHFFFAOYSA-N 4-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NC1CCCCC1)S2 CDMSUMPDCNIYMR-UHFFFAOYSA-N 0.000 description 3
- MGRONUXQOUJYNK-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 MGRONUXQOUJYNK-UHFFFAOYSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- SBBIHHYSFMEQLY-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(F)C(Cl)=C1 SBBIHHYSFMEQLY-UHFFFAOYSA-N 0.000 description 3
- DXOLBUFYHXFWOJ-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=C(F)C(Cl)=C1 DXOLBUFYHXFWOJ-UHFFFAOYSA-N 0.000 description 3
- KCEAUFQNCXVWCA-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(Cl)=C1 KCEAUFQNCXVWCA-UHFFFAOYSA-N 0.000 description 3
- NGSIFTAYSMYXTJ-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 NGSIFTAYSMYXTJ-UHFFFAOYSA-N 0.000 description 3
- OPABNPDQMVRCEB-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(Cl)C=C1 OPABNPDQMVRCEB-UHFFFAOYSA-N 0.000 description 3
- GEYVPESZHDWDHI-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2-pyridin-2-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C2N1N=C(NCCC=1N=CC=CC=1)S2 GEYVPESZHDWDHI-UHFFFAOYSA-N 0.000 description 3
- ZGLYOLGEKPEIMV-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 ZGLYOLGEKPEIMV-UHFFFAOYSA-N 0.000 description 3
- JREXMIYNBFAMJU-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(N(C)C)=C1 JREXMIYNBFAMJU-UHFFFAOYSA-N 0.000 description 3
- VYJFLCDCGRINLI-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(N(C)C)=C1 VYJFLCDCGRINLI-UHFFFAOYSA-N 0.000 description 3
- ATBXLDQFSPCJLD-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 ATBXLDQFSPCJLD-UHFFFAOYSA-N 0.000 description 3
- XSMDFTBEEDUNGM-UHFFFAOYSA-N 5-naphthalen-2-yl-n-(2-phenoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCCOC1=CC=CC=C1 XSMDFTBEEDUNGM-UHFFFAOYSA-N 0.000 description 3
- WUPDEFYLWCCWJX-UHFFFAOYSA-N 5-naphthalen-2-yl-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCC1CCOCC1 WUPDEFYLWCCWJX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- MKIALVWVCSUSRO-UHFFFAOYSA-N N-(cyclopropylmethyl)-5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)c1cccc(c1)-c1cnc2sc(NCC3CC3)nn12 MKIALVWVCSUSRO-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 3
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- BATGAUYGEAYXNU-UHFFFAOYSA-N n-(2-methoxyethyl)-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC=CC2=CC(C=3N4N=C(SC4=NC=3)NCCOC)=CC=C21 BATGAUYGEAYXNU-UHFFFAOYSA-N 0.000 description 3
- FMMBFVSBNJEBPN-UHFFFAOYSA-N n-(2-methylpropyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(OC(F)(F)F)=C1 FMMBFVSBNJEBPN-UHFFFAOYSA-N 0.000 description 3
- CGYQFWLWTXHONV-UHFFFAOYSA-N n-(2-methylpropyl)-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC=CC2=CC(C=3N4N=C(SC4=NC=3)NCC(C)C)=CC=C21 CGYQFWLWTXHONV-UHFFFAOYSA-N 0.000 description 3
- OFKATVBCGAQCJL-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical class FC(F)(F)OC1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 OFKATVBCGAQCJL-UHFFFAOYSA-N 0.000 description 3
- KBEMEQFTEFCAAM-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)-5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical class FC(F)(F)C1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 KBEMEQFTEFCAAM-UHFFFAOYSA-N 0.000 description 3
- FMADWCXZBYLZOM-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCC1CC1 FMADWCXZBYLZOM-UHFFFAOYSA-N 0.000 description 3
- KTQBZSZFKGAOLJ-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 KTQBZSZFKGAOLJ-UHFFFAOYSA-N 0.000 description 3
- UEJFLXXWFFAQRF-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C=CC=C2)C2=C1 UEJFLXXWFFAQRF-UHFFFAOYSA-N 0.000 description 3
- BNNZYNQIOACACQ-UHFFFAOYSA-N n-[3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 BNNZYNQIOACACQ-UHFFFAOYSA-N 0.000 description 3
- GYJKOOQZYHHTTO-UHFFFAOYSA-N n-[3-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCC=4OC=CC=4)SC3=NC=2)=C1 GYJKOOQZYHHTTO-UHFFFAOYSA-N 0.000 description 3
- BTYWULCWEDPYQF-UHFFFAOYSA-N n-[3-[2-(thiophen-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 BTYWULCWEDPYQF-UHFFFAOYSA-N 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000000542 sulfonic acid group Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013022 venting Methods 0.000 description 3
- VYEWTHXZHHATTA-UHFFFAOYSA-N (4-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=C(B(O)O)C=C1 VYEWTHXZHHATTA-UHFFFAOYSA-N 0.000 description 2
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 2
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QCEBMBOQEGHBQA-UHFFFAOYSA-N 1-[4-[(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylamino]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1NCC1=CN=C2N1N=C(Br)S2 QCEBMBOQEGHBQA-UHFFFAOYSA-N 0.000 description 2
- WTHUZDCMEMDVAV-UHFFFAOYSA-N 2,5-diphenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C=1N=C2SC(C=3C=CC=CC=3)=NN2C=1C1=CC=CC=C1 WTHUZDCMEMDVAV-UHFFFAOYSA-N 0.000 description 2
- BIYUHJDISSCHKV-UHFFFAOYSA-N 2-(4-fluorophenoxy)-5-iodoimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1OC(S1)=NN2C1=NC=C2I BIYUHJDISSCHKV-UHFFFAOYSA-N 0.000 description 2
- UOFCXVBAUZFSQT-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(NCC3CC3)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 UOFCXVBAUZFSQT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WMLFBYOCNPFETO-UHFFFAOYSA-N 2-bromo-3h-imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide Chemical class C1=CN=C2SC(S(=O)(=O)N)(Br)NN21 WMLFBYOCNPFETO-UHFFFAOYSA-N 0.000 description 2
- UMGUTIXTGLAOKQ-UHFFFAOYSA-N 2-bromo-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde Chemical compound S1C(Br)=NN2C1NC=C2C=O UMGUTIXTGLAOKQ-UHFFFAOYSA-N 0.000 description 2
- HHBVKSDIEPYPPS-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonic acid Chemical compound S1C(Br)=NN2C(S(=O)(=O)O)=CN=C21 HHBVKSDIEPYPPS-UHFFFAOYSA-N 0.000 description 2
- LCAQQRBVDSLLBW-UHFFFAOYSA-N 2-bromoimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonyl chloride Chemical compound S1C(Br)=NN2C(S(=O)(=O)Cl)=CN=C21 LCAQQRBVDSLLBW-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- OEGHJICHYPFZQI-UHFFFAOYSA-N 2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound S1C2=NC=CN2N=C1C1=CC=CC=C1 OEGHJICHYPFZQI-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- KOFOWCSAPHLJNB-UHFFFAOYSA-N 4-(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)sulfonylmorpholine Chemical compound C=1N=C2SC(Br)=NN2C=1S(=O)(=O)N1CCOCC1 KOFOWCSAPHLJNB-UHFFFAOYSA-N 0.000 description 2
- WCMVGMVOYZYSQE-UHFFFAOYSA-N 4-[2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 WCMVGMVOYZYSQE-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VFADMXXTEOMORM-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC(C)C)S2 VFADMXXTEOMORM-UHFFFAOYSA-N 0.000 description 2
- TYXNKCHCNDVPAV-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-[(2-methylphenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC=4C(=CC=CC=4)C)SC3=NC=2)=C1 TYXNKCHCNDVPAV-UHFFFAOYSA-N 0.000 description 2
- CYCKYOCVGGSLSC-UHFFFAOYSA-N 5-iodo-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound N=1N2C(I)=CN=C2SC=1C1=CC=CC=C1 CYCKYOCVGGSLSC-UHFFFAOYSA-N 0.000 description 2
- KSCWJLBBCJEHIQ-UHFFFAOYSA-N 5-iodo-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=CN=C2SC(NCC(C)C)=NN21 KSCWJLBBCJEHIQ-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- YZQQHZXHCXAJAV-UHFFFAOYSA-N [3-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=CC(B(O)O)=C1 YZQQHZXHCXAJAV-UHFFFAOYSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
- 230000010250 cytokine signaling pathway Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical group N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- FQIMHLFOFUNWEL-UHFFFAOYSA-N n-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1NC(S1)=NN2C1=NC=C2 FQIMHLFOFUNWEL-UHFFFAOYSA-N 0.000 description 2
- DDDUOINJEICOML-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CC1CNC(SC1=NC=2)=NN1C=2CN1CCOCC1 DDDUOINJEICOML-UHFFFAOYSA-N 0.000 description 2
- QEMBTRRIBDINCB-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CC1CNC(SC1=NC=2)=NN1C=2C1=CC=CC=C1 QEMBTRRIBDINCB-UHFFFAOYSA-N 0.000 description 2
- VSNRREGQNSELCB-UHFFFAOYSA-N n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C=CN=C2SC=1NCC1CC1 VSNRREGQNSELCB-UHFFFAOYSA-N 0.000 description 2
- BFFCPECCXKDDEO-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(S1)=NN2C1=NC=C2I BFFCPECCXKDDEO-UHFFFAOYSA-N 0.000 description 2
- CVFQBICVTJEPDF-UHFFFAOYSA-N n-ethyl-2-(ethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound CCNS(=O)(=O)C1=CN=C2SC(NCC)=NN21 CVFQBICVTJEPDF-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000006478 transmetalation reaction Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- NLTUNPUDLJXLOC-VMPITWQZSA-N (e)-3-[4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 NLTUNPUDLJXLOC-VMPITWQZSA-N 0.000 description 1
- NIVAQFKVLKYUKV-VMPITWQZSA-N (e)-3-[4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1OC=CC=1)S2 NIVAQFKVLKYUKV-VMPITWQZSA-N 0.000 description 1
- BPRSISHQMLQOMN-VMPITWQZSA-N (e)-3-[4-[2-(propylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C=1N=C2SC(NCCC)=NN2C=1C1=CC=C(\C=C\C(O)=O)C=C1 BPRSISHQMLQOMN-VMPITWQZSA-N 0.000 description 1
- ANCKIGZDEUUTJS-XBXARRHUSA-N (e)-3-[4-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1C=C(Cl)C(Cl)=CC=1)S2 ANCKIGZDEUUTJS-XBXARRHUSA-N 0.000 description 1
- JBKQMMZFNCFUGR-LHRNQBEKSA-N (e)-3-[4-[2-[[(2s)-1-hydroxy-3-methylbutan-2-yl]amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C=1N=C2SC(N[C@H](CO)C(C)C)=NN2C=1C1=CC=C(\C=C\C(O)=O)C=C1 JBKQMMZFNCFUGR-LHRNQBEKSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- RUAOUHQNNBBMGS-UHFFFAOYSA-N 1,1,1,2-tetrachloro-2,2-diiodoethane Chemical compound ClC(Cl)(Cl)C(Cl)(I)I RUAOUHQNNBBMGS-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- JNVXRQOSRUDXDY-UHFFFAOYSA-N 1,1-diiodoethane Chemical compound CC(I)I JNVXRQOSRUDXDY-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- UXTIRLFDCHFIID-UHFFFAOYSA-N 1,3,4-thiadiazole-2-carbaldehyde Chemical compound O=CC1=NN=CS1 UXTIRLFDCHFIID-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- HERGTCZBTXKUKG-UHFFFAOYSA-N 1-[2-[[5-(3-methylsulfonylphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound CS(=O)(=O)C1=CC=CC(C=2N3N=C(NCCN4C(NCC4)=O)SC3=NC=2)=C1 HERGTCZBTXKUKG-UHFFFAOYSA-N 0.000 description 1
- QBUHYMHIPRUAHM-UHFFFAOYSA-N 1-[3-[2-(1,3-benzodioxol-5-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4C=C5OCOC5=CC=4)SC3=NC=2)=C1 QBUHYMHIPRUAHM-UHFFFAOYSA-N 0.000 description 1
- WLOXPBZMNNSUGP-UHFFFAOYSA-N 1-[3-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(C(C)=O)=C1 WLOXPBZMNNSUGP-UHFFFAOYSA-N 0.000 description 1
- RVXYXVVILUCCAH-UHFFFAOYSA-N 1-[3-[2-(2-morpholin-4-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCCN4CCOCC4)SC3=NC=2)=C1 RVXYXVVILUCCAH-UHFFFAOYSA-N 0.000 description 1
- PJGLCBCBNJMVCD-UHFFFAOYSA-N 1-[3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 PJGLCBCBNJMVCD-UHFFFAOYSA-N 0.000 description 1
- LQFGVJDPWYFUHU-UHFFFAOYSA-N 1-[3-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4OC=CC=4)SC3=NC=2)=C1 LQFGVJDPWYFUHU-UHFFFAOYSA-N 0.000 description 1
- NYRUEMXFVPUIIS-UHFFFAOYSA-N 1-[3-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2N3N=C(NCC=4C=C(Cl)C(Cl)=CC=4)SC3=NC=2)=C1 NYRUEMXFVPUIIS-UHFFFAOYSA-N 0.000 description 1
- WNNMDSHQQSETLW-UHFFFAOYSA-N 1-[3-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(C(C)=O)=C1 WNNMDSHQQSETLW-UHFFFAOYSA-N 0.000 description 1
- ISRPTTSIDVGQRW-UHFFFAOYSA-N 1-[3-[6-chloro-2-(2-methylpropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]ethanone Chemical compound ClC=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(C(C)=O)=C1 ISRPTTSIDVGQRW-UHFFFAOYSA-N 0.000 description 1
- QORVTJMUYZLSGU-UHFFFAOYSA-N 1-[3-[[2-(2-methoxyethylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylamino]phenyl]ethanone Chemical compound S1C(NCCOC)=NN2C1NC=C2CNC1=CC=CC(C(C)=O)=C1 QORVTJMUYZLSGU-UHFFFAOYSA-N 0.000 description 1
- WRTXUFKSQJFCCH-UHFFFAOYSA-N 1-[3-[[2-(2-methylpropylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylamino]phenyl]ethanone Chemical compound S1C(NCC(C)C)=NN2C1NC=C2CNC1=CC=CC(C(C)=O)=C1 WRTXUFKSQJFCCH-UHFFFAOYSA-N 0.000 description 1
- QVDNROXSSNIRTQ-UHFFFAOYSA-N 1-[3-[[2-(dimethylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylamino]phenyl]ethanone Chemical compound S1C(N(C)C)=NN2C1NC=C2CNC1=CC=CC(C(C)=O)=C1 QVDNROXSSNIRTQ-UHFFFAOYSA-N 0.000 description 1
- GONRJIWQOBRGOR-UHFFFAOYSA-N 1-[4-[5-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]phenyl]ethanone Chemical compound C1=CC(OC)=CC=C1CNC1=CN=C2N1N=C(C=1C=CC(=CC=1)C(C)=O)S2 GONRJIWQOBRGOR-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- CDKCEZNPAYWORX-UHFFFAOYSA-N 1-tert-butyl-4-(4-tert-butylphenyl)benzene Chemical group C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 CDKCEZNPAYWORX-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- AISKMOQBOFWLFR-UHFFFAOYSA-N 2-(2-methylpropylamino)-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 AISKMOQBOFWLFR-UHFFFAOYSA-N 0.000 description 1
- JRNUZJGZJZOYAB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound C1=C(OC)C(OC)=CC=C1C(S1)=NN2C1=NC=C2NC1CCOCC1 JRNUZJGZJZOYAB-UHFFFAOYSA-N 0.000 description 1
- IRBKTCFRZKQHMD-UHFFFAOYSA-N 2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1OC(S1)=NN2C1=NC=C2 IRBKTCFRZKQHMD-UHFFFAOYSA-N 0.000 description 1
- KOXRRHFBOQALQJ-UHFFFAOYSA-N 2-(dimethylamino)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde Chemical compound S1C(N(C)C)=NN2C1NC=C2C=O KOXRRHFBOQALQJ-UHFFFAOYSA-N 0.000 description 1
- HEWKCLUEWLJWBV-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2S(=O)(=O)NC1=CC=CC=C1 HEWKCLUEWLJWBV-UHFFFAOYSA-N 0.000 description 1
- UJYCDDNNOBCLSZ-UHFFFAOYSA-N 2-[(5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]ethanol Chemical compound C1=CC=CC2=CC(C=3N4N=C(SC4=NC=3)NCCO)=CC=C21 UJYCDDNNOBCLSZ-UHFFFAOYSA-N 0.000 description 1
- GWMOKMDYNBJFGH-UHFFFAOYSA-N 2-[(6-fluoro-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]ethanol Chemical compound C1=CC=CC2=CC(C=3N4N=C(SC4=NC=3F)NCCO)=CC=C21 GWMOKMDYNBJFGH-UHFFFAOYSA-N 0.000 description 1
- OJBVAXSBHIOYHY-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]oxy-n-methylacetamide Chemical compound C=1N=C2SC(OCC(=O)NC)=NN2C=1C1=CC=C(Cl)C=C1 OJBVAXSBHIOYHY-UHFFFAOYSA-N 0.000 description 1
- BAXVCXWQHQBHAR-UHFFFAOYSA-N 2-[[2-[(3,4-dichlorophenyl)methylamino]-6-methylimidazo[2,1-b][1,3,4]thiadiazole-5-carbonyl]amino]acetic acid Chemical compound N=1N2C(C(=O)NCC(O)=O)=C(C)N=C2SC=1NCC1=CC=C(Cl)C(Cl)=C1 BAXVCXWQHQBHAR-UHFFFAOYSA-N 0.000 description 1
- AEGXSYHUTNVRRI-UHFFFAOYSA-N 2-[[5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]butan-1-ol Chemical compound C=1N=C2SC(NC(CO)CC)=NN2C=1C1=CC=C(OC)C(OC)=C1 AEGXSYHUTNVRRI-UHFFFAOYSA-N 0.000 description 1
- FEDUPUWLSQTTTC-UHFFFAOYSA-N 2-[[5-(3-chloro-4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]ethanol Chemical compound C=1N=C2SC(NCCO)=NN2C=1C1=CC=C(F)C(Cl)=C1 FEDUPUWLSQTTTC-UHFFFAOYSA-N 0.000 description 1
- TXHOKZKOFUTJRC-UHFFFAOYSA-N 2-[[5-(3-cyanophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetic acid Chemical compound C=1N=C2SC(NCC(=O)O)=NN2C=1C1=CC=CC(C#N)=C1 TXHOKZKOFUTJRC-UHFFFAOYSA-N 0.000 description 1
- DKHNAOKCCZCUJO-UHFFFAOYSA-N 2-[[5-(3-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetamide Chemical compound C=1N=C2SC(NCC(=O)N)=NN2C=1C1=CC=CC(F)=C1 DKHNAOKCCZCUJO-UHFFFAOYSA-N 0.000 description 1
- FHTJLIVTWPPTTI-UHFFFAOYSA-N 2-[[5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]acetamide Chemical compound C=1N=C2SC(NCC(=O)N)=NN2C=1C1=CC=CC(C(F)(F)F)=C1 FHTJLIVTWPPTTI-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- VFOMZTWMSYRKRC-UHFFFAOYSA-N 2-bromo-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde;3-bromo-2,4-dihydroimidazo[4,5-d][1,3]thiazole Chemical compound N1=CNC2=C1SCN2Br.S1C(Br)=NN2C1NC=C2C=O VFOMZTWMSYRKRC-UHFFFAOYSA-N 0.000 description 1
- CWTLPSMNMHQWCV-UHFFFAOYSA-N 2-bromo-n-ethylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound S1C(Br)=NN2C(S(=O)(=O)NCC)=CN=C21 CWTLPSMNMHQWCV-UHFFFAOYSA-N 0.000 description 1
- QTNKRICUUZBICH-UHFFFAOYSA-N 2-bromo-n-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound C=1N=C2SC(Br)=NN2C=1S(=O)(=O)NC1=CC=CC=C1 QTNKRICUUZBICH-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PXVCQYZKMBRTIW-UHFFFAOYSA-N 2-methoxy-4-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(O)C(OC)=C1 PXVCQYZKMBRTIW-UHFFFAOYSA-N 0.000 description 1
- NOSVNPMFKHWHTE-UHFFFAOYSA-N 2-methoxy-n-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound C=1N=C2SC(OC)=NN2C=1NC1=CC=CC(C(F)(F)F)=C1 NOSVNPMFKHWHTE-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- PDSYHMDJYQFIGQ-UHFFFAOYSA-N 2-phenyl-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C=1N=C2SC(C=3C=CC=CC=3)=NN2C=1C1=CC=CN=C1 PDSYHMDJYQFIGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- YKXHTEHVFNYIJO-UHFFFAOYSA-N 3-[2-(2-pyrazin-2-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N3N=C(NCCC=4N=CC=NC=4)SC3=NC=2)=C1 YKXHTEHVFNYIJO-UHFFFAOYSA-N 0.000 description 1
- WCBJZOUNBRGCLA-UHFFFAOYSA-N 3-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethylaniline 2-(4-fluorophenoxy)-5-iodoimidazo[2,1-b][1,3,4]thiadiazole Chemical compound FC1=CC=C(OC2=NN3C(S2)=NC=C3I)C=C1.FC1=CC=C(OC3=NN2C(S3)=NC=C2C=2C=C(C=CC2)N(C)C)C=C1 WCBJZOUNBRGCLA-UHFFFAOYSA-N 0.000 description 1
- YKGMCRDGQBHBRZ-UHFFFAOYSA-N 3-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(C=2N3N=C(OC=4C=CC(F)=CC=4)SC3=NC=2)=C1 YKGMCRDGQBHBRZ-UHFFFAOYSA-N 0.000 description 1
- WNOSANZIJVUADV-UHFFFAOYSA-N 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 WNOSANZIJVUADV-UHFFFAOYSA-N 0.000 description 1
- QXZWYIBQYBPJSG-UHFFFAOYSA-N 3-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n-[2-(dimethylamino)ethyl]benzamide Chemical compound CN(C)CCNC(=O)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 QXZWYIBQYBPJSG-UHFFFAOYSA-N 0.000 description 1
- RBUSWWHXOSBUDQ-UHFFFAOYSA-N 3-[[2-(3-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N3N=C(SC3=NC=2)C=2C=C(Cl)C=CC=2)=C1 RBUSWWHXOSBUDQ-UHFFFAOYSA-N 0.000 description 1
- XVKPPQLTLGXKRX-UHFFFAOYSA-N 3-acetamido-n-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]propanamide Chemical compound N=1N2C(NC(=O)CCNC(=O)C)=CN=C2SC=1NCC1=CC=C(Cl)C(Cl)=C1 XVKPPQLTLGXKRX-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- KCEKCKYZZHREFI-UHFFFAOYSA-N 3h-thiadiazol-2-amine Chemical compound NN1NC=CS1 KCEKCKYZZHREFI-UHFFFAOYSA-N 0.000 description 1
- JYNJDULKNSARKX-UHFFFAOYSA-N 4-[(2-phenylsulfanylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)amino]benzonitrile Chemical compound C1=CC(C#N)=CC=C1NC1=CN=C2N1N=C(SC=1C=CC=CC=1)S2 JYNJDULKNSARKX-UHFFFAOYSA-N 0.000 description 1
- OIFFZYUSDDUHAX-UHFFFAOYSA-N 4-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzonitrile Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(C#N)C=C1 OIFFZYUSDDUHAX-UHFFFAOYSA-N 0.000 description 1
- WDTBCLHSFVDQFR-UHFFFAOYSA-N 4-[2-(2-phenylethynyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(C#CC=1C=CC=CC=1)S2 WDTBCLHSFVDQFR-UHFFFAOYSA-N 0.000 description 1
- IUZXAVUPOYMEGA-UHFFFAOYSA-N 4-[2-(3-hydroxypropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzonitrile Chemical compound C=1N=C2SC(NCCCO)=NN2C=1C1=CC=C(C#N)C=C1 IUZXAVUPOYMEGA-UHFFFAOYSA-N 0.000 description 1
- BCAKJJZKSLTUOK-UHFFFAOYSA-N 4-[2-(4-fluoroanilino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NC=1C=CC(F)=CC=1)S2 BCAKJJZKSLTUOK-UHFFFAOYSA-N 0.000 description 1
- RBKDSSSWSMXHNY-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(OC=1C=CC(F)=CC=1)S2 RBKDSSSWSMXHNY-UHFFFAOYSA-N 0.000 description 1
- YYFVZYSDAYKPHY-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 YYFVZYSDAYKPHY-UHFFFAOYSA-N 0.000 description 1
- TXSMZUMNTPVXND-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-n-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 TXSMZUMNTPVXND-UHFFFAOYSA-N 0.000 description 1
- DCWSYLUITYNIGO-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 DCWSYLUITYNIGO-UHFFFAOYSA-N 0.000 description 1
- LLKIZECKWXVXTN-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NCC=4OC=CC=4)SC3=NC=2)=C1 LLKIZECKWXVXTN-UHFFFAOYSA-N 0.000 description 1
- IMVSCJJYRZZBMO-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2N3N=C(NCC=4OC=CC=4)SC3=NC=2)=C1 IMVSCJJYRZZBMO-UHFFFAOYSA-N 0.000 description 1
- AZBLYHKQMKDTLM-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1OC=CC=1)S2 AZBLYHKQMKDTLM-UHFFFAOYSA-N 0.000 description 1
- CYSSZRBXBMTMJN-UHFFFAOYSA-N 4-[2-(furan-2-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C2N1N=C(NCC=1OC=CC=1)S2 CYSSZRBXBMTMJN-UHFFFAOYSA-N 0.000 description 1
- RZVALJNOJASENH-UHFFFAOYSA-N 4-[2-(oxan-4-ylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NC1CCOCC1)S2 RZVALJNOJASENH-UHFFFAOYSA-N 0.000 description 1
- RCTCRXQSEBAUTN-UHFFFAOYSA-N 4-[2-[(3,4-dichlorophenyl)methylamino]-6-methylimidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound N=1N2C(C=3C=CC(=CC=3)C(O)=O)=C(C)N=C2SC=1NCC1=CC=C(Cl)C(Cl)=C1 RCTCRXQSEBAUTN-UHFFFAOYSA-N 0.000 description 1
- OUQJCXXWLCNAMH-UHFFFAOYSA-N 4-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1C=C(Cl)C(Cl)=CC=1)S2 OUQJCXXWLCNAMH-UHFFFAOYSA-N 0.000 description 1
- UYBUQAUXGAHMEO-UHFFFAOYSA-N 4-[2-[(3-chlorobenzoyl)amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NC(=O)C=1C=C(Cl)C=CC=1)S2 UYBUQAUXGAHMEO-UHFFFAOYSA-N 0.000 description 1
- NJYLAAKOAVHNDS-UHFFFAOYSA-N 4-[2-[(3-chlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C2N1N=C(NCC=1C=C(Cl)C=CC=1)S2 NJYLAAKOAVHNDS-UHFFFAOYSA-N 0.000 description 1
- GPTLOEFMTXIAFG-UHFFFAOYSA-N 4-[2-[(4-chloro-3-fluorophenyl)methoxy]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]morpholine Chemical compound C1=C(Cl)C(F)=CC(COC=2SC3=NC=C(N3N=2)N2CCOCC2)=C1 GPTLOEFMTXIAFG-UHFFFAOYSA-N 0.000 description 1
- QNNMNDPDEFCPEL-UHFFFAOYSA-N 4-[2-[(4-methoxyphenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C(O)=O)C=C1 QNNMNDPDEFCPEL-UHFFFAOYSA-N 0.000 description 1
- QSJRRKDQFXJZPP-UHFFFAOYSA-N 4-[2-[[2-(methylamino)-2-oxoethyl]amino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzoic acid Chemical compound C=1N=C2SC(NCC(=O)NC)=NN2C=1C1=CC=C(C(O)=O)C=C1 QSJRRKDQFXJZPP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ARJWNXFXDITWMQ-UHFFFAOYSA-N 4-[[(5-cyclohexylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(S1)=NN2C1=NC=C2C1CCCCC1 ARJWNXFXDITWMQ-UHFFFAOYSA-N 0.000 description 1
- OXLQGNMLAWCZDG-UHFFFAOYSA-N 4-[[(5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)amino]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C=CC=C2)C2=C1 OXLQGNMLAWCZDG-UHFFFAOYSA-N 0.000 description 1
- GGJRTLFUXVJJJE-UHFFFAOYSA-N 4-[[2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-carbonyl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)C1=CN=C2N1N=C(NCC1CC1)S2 GGJRTLFUXVJJJE-UHFFFAOYSA-N 0.000 description 1
- DOKIHNBETLEOKV-UHFFFAOYSA-N 4-[[5-[3-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC(S1)=NN2C1=NC=C2C1=CC=CC(C(F)(F)F)=C1 DOKIHNBETLEOKV-UHFFFAOYSA-N 0.000 description 1
- YTSADIUOTOUBFV-UHFFFAOYSA-N 4-[[[5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]amino]methyl]benzenesulfonamide Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(=CC=1)S(N)(=O)=O)S2 YTSADIUOTOUBFV-UHFFFAOYSA-N 0.000 description 1
- STABAPSYCQFWOK-UHFFFAOYSA-N 4-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=C(Cl)C=C1 STABAPSYCQFWOK-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- PCDJGXGQWRWWOM-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NN(C)C=C1C1=CN=C2N1N=C(NCC=1SC=CC=1)S2 PCDJGXGQWRWWOM-UHFFFAOYSA-N 0.000 description 1
- ISMJVFZMAKGARB-UHFFFAOYSA-N 5-(1h-indol-2-yl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1COCCC1NC(S1)=NN2C1=NC=C2C1=CC2=CC=CC=C2N1 ISMJVFZMAKGARB-UHFFFAOYSA-N 0.000 description 1
- RGIWIBHXIJDYMR-UHFFFAOYSA-N 5-(1h-indol-6-yl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=C2NC=CC2=CC=C1C(N1N=2)=CN=C1SC=2C1=CC=CC=C1 RGIWIBHXIJDYMR-UHFFFAOYSA-N 0.000 description 1
- TWEKLWVMADRAJK-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC=C1Cl TWEKLWVMADRAJK-UHFFFAOYSA-N 0.000 description 1
- OKFNARGTEHFFSO-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 OKFNARGTEHFFSO-UHFFFAOYSA-N 0.000 description 1
- FSXZHSBSMPBIHD-UHFFFAOYSA-N 5-(2-chlorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 FSXZHSBSMPBIHD-UHFFFAOYSA-N 0.000 description 1
- DWFWVCHMFZGQFM-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NCC(C)C)S2 DWFWVCHMFZGQFM-UHFFFAOYSA-N 0.000 description 1
- CCEKYNCIKDHLBO-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NC1CCOCC1)S2 CCEKYNCIKDHLBO-UHFFFAOYSA-N 0.000 description 1
- DNRXQBUTUCTHDF-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-n-propylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCC)=NN2C=1C1=CC=C(OC)C(OC)=C1 DNRXQBUTUCTHDF-UHFFFAOYSA-N 0.000 description 1
- UHKTZSPAXISGQL-UHFFFAOYSA-N 5-(3,5-difluorophenyl)-n-(2-morpholin-4-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC1=CC(F)=CC(C=2N3N=C(NCCN4CCOCC4)SC3=NC=2)=C1 UHKTZSPAXISGQL-UHFFFAOYSA-N 0.000 description 1
- GNCONOLRZNPQDA-UHFFFAOYSA-N 5-(3-aminophenyl)-n-[2-(5-methyl-1h-pyrazol-4-yl)ethyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N1N=CC(CCNC=2SC3=NC=C(N3N=2)C=2C=C(N)C=CC=2)=C1C GNCONOLRZNPQDA-UHFFFAOYSA-N 0.000 description 1
- MFEIAYFOMNIFSE-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenoxy)-n-(2,2-dimethylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)(C)C)=NN2C=1OC1=CC=C(F)C(Cl)=C1 MFEIAYFOMNIFSE-UHFFFAOYSA-N 0.000 description 1
- NWFJOWJTGMOMJG-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-n-(1h-pyrrol-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(F)=CC=C1C1=CN=C2N1N=C(NCC=1NC=CC=1)S2 NWFJOWJTGMOMJG-UHFFFAOYSA-N 0.000 description 1
- CDBZUHPKCWJXHR-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-(cyclopropylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 CDBZUHPKCWJXHR-UHFFFAOYSA-N 0.000 description 1
- URUYOPINPBEWQF-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(Cl)=C1 URUYOPINPBEWQF-UHFFFAOYSA-N 0.000 description 1
- YRZVPHJQUGHMOJ-UHFFFAOYSA-N 5-(3-fluorophenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(F)=C1 YRZVPHJQUGHMOJ-UHFFFAOYSA-N 0.000 description 1
- DZQUEOZCGAAUTO-UHFFFAOYSA-N 5-(3-fluorophenyl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC1=CC=CC(C=2N3N=C(NCC4CCOCC4)SC3=NC=2)=C1 DZQUEOZCGAAUTO-UHFFFAOYSA-N 0.000 description 1
- TWKYOMMITBIKND-UHFFFAOYSA-N 5-(4-aminophenyl)-n-(pyridin-3-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(N)=CC=C1C1=CN=C2N1N=C(NCC=1C=NC=CC=1)S2 TWKYOMMITBIKND-UHFFFAOYSA-N 0.000 description 1
- GJERHEXXQXGUDH-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=C(Cl)C=C1 GJERHEXXQXGUDH-UHFFFAOYSA-N 0.000 description 1
- KXEKDQIECACWFS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(Cl)C=C1 KXEKDQIECACWFS-UHFFFAOYSA-N 0.000 description 1
- INWQOVNJGBKZIT-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazole Chemical compound C1=CC(F)=CC=C1C1=CN=C2N1N=C(C=1C=CC=CC=1)S2 INWQOVNJGBKZIT-UHFFFAOYSA-N 0.000 description 1
- JLMBQTZSDTWJNO-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC(C)C)SC3=NC=2)=C1 JLMBQTZSDTWJNO-UHFFFAOYSA-N 0.000 description 1
- HIMBVBHJQNZPGV-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(oxan-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NC4CCOCC4)SC3=NC=2)=C1 HIMBVBHJQNZPGV-UHFFFAOYSA-N 0.000 description 1
- IKAJIIIXTORULG-UHFFFAOYSA-N 5-(5-methoxypyridin-3-yl)-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC=4SC=CC=4)SC3=NC=2)=C1 IKAJIIIXTORULG-UHFFFAOYSA-N 0.000 description 1
- VQNVUAUJUIRXSL-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(oxan-4-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical class C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 VQNVUAUJUIRXSL-UHFFFAOYSA-N 0.000 description 1
- ZGRBXIQRUFYTAI-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1SC=CC=1)S2 ZGRBXIQRUFYTAI-UHFFFAOYSA-N 0.000 description 1
- CARXPXGXWCKBJL-UHFFFAOYSA-N 5-[(3-chloro-4-fluoroanilino)methyl]-n-(2-methylpropyl)-7,7a-dihydroimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound S1C(NCC(C)C)=NN2C1NC=C2CNC1=CC=C(F)C(Cl)=C1 CARXPXGXWCKBJL-UHFFFAOYSA-N 0.000 description 1
- JEXIXPKIERCDHG-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC=4C=CC(F)=CC=4)SC3=NC=2)=C1 JEXIXPKIERCDHG-UHFFFAOYSA-N 0.000 description 1
- GLYQQFBHCFPEEU-UHFFFAOYSA-N 5-bromo-1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=C(Br)S1 GLYQQFBHCFPEEU-UHFFFAOYSA-N 0.000 description 1
- CJFCWJPEXFBTQS-UHFFFAOYSA-N 5-iodo-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=CN=C2SC(NCCOC)=NN21 CJFCWJPEXFBTQS-UHFFFAOYSA-N 0.000 description 1
- QVIMKBGZYDTTOU-UHFFFAOYSA-N 5-iodo-n-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1NC(S1)=NN2C1=NC=C2I QVIMKBGZYDTTOU-UHFFFAOYSA-N 0.000 description 1
- COUVXMHSERVLPZ-UHFFFAOYSA-N 5-naphthalen-2-yl-n-(2-pyridin-2-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCCC1=CC=CC=N1 COUVXMHSERVLPZ-UHFFFAOYSA-N 0.000 description 1
- BJHAGDWMARLZGE-UHFFFAOYSA-N 5-naphthalen-2-yl-n-(thiophen-2-ylmethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CC=CC4=CC=3)=CN=C2SC=1NCC1=CC=CS1 BJHAGDWMARLZGE-UHFFFAOYSA-N 0.000 description 1
- QJSZXZWMKYASRV-UHFFFAOYSA-N 5-phenyl-3h-thiadiazol-2-amine Chemical compound S1N(N)NC=C1C1=CC=CC=C1 QJSZXZWMKYASRV-UHFFFAOYSA-N 0.000 description 1
- GEXFPVPQBONTAX-UHFFFAOYSA-N 5-phenyl-n-(2-pyridin-2-ylethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=CC=CC=3)=CN=C2SC=1NCCC1=CC=CC=N1 GEXFPVPQBONTAX-UHFFFAOYSA-N 0.000 description 1
- GGRZTZVOZQAFCY-UHFFFAOYSA-N 6-chloro-5-(3,4-dimethoxyphenyl)-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound ClC=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(OC)C(OC)=C1 GGRZTZVOZQAFCY-UHFFFAOYSA-N 0.000 description 1
- NFVXCEPOQUHJRX-UHFFFAOYSA-N 6-chloro-5-iodo-n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=C(Cl)N=C2SC(NCCOC)=NN21 NFVXCEPOQUHJRX-UHFFFAOYSA-N 0.000 description 1
- OQFGAXWLSQXCBP-UHFFFAOYSA-N 6-chloro-5-iodo-n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound IC1=C(Cl)N=C2SC(NCC(C)C)=NN21 OQFGAXWLSQXCBP-UHFFFAOYSA-N 0.000 description 1
- XDZAUUQMNKFTAJ-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-5-[3-(dimethylamino)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2Cl)=C1 XDZAUUQMNKFTAJ-UHFFFAOYSA-N 0.000 description 1
- AOVURLLOSHBESU-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(I)=C(Cl)N=C2SC=1NCC1CC1 AOVURLLOSHBESU-UHFFFAOYSA-N 0.000 description 1
- UXJOPIADSJBWJO-UHFFFAOYSA-N 6-chloro-n-[(4-fluorophenyl)methyl]-5-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1C1=C(Cl)N=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 UXJOPIADSJBWJO-UHFFFAOYSA-N 0.000 description 1
- NGTZLYHDVCVIEY-UHFFFAOYSA-N 6-chloro-n-[(4-fluorophenyl)methyl]-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC(Cl)=C2I NGTZLYHDVCVIEY-UHFFFAOYSA-N 0.000 description 1
- XXROMDIIDAKWDD-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]octane Chemical compound C1C2COC1CCC2 XXROMDIIDAKWDD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- DCLNFTWENAUIPQ-UHFFFAOYSA-N BrC1=NN2C(S1)=NC=C2S(=O)(=O)O.BrC2=NN1C(S2)=NC=C1S(=O)(=O)Cl Chemical compound BrC1=NN2C(S1)=NC=C2S(=O)(=O)O.BrC2=NN1C(S2)=NC=C1S(=O)(=O)Cl DCLNFTWENAUIPQ-UHFFFAOYSA-N 0.000 description 1
- FXTINVHQDGXVAQ-UHFFFAOYSA-N BrC1=NN=C(S1)N.BrC1=NN2C(S1)=NC=C2 Chemical compound BrC1=NN=C(S1)N.BrC1=NN2C(S1)=NC=C2 FXTINVHQDGXVAQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- CRXNCKJXYUXZEM-UHFFFAOYSA-M C([O-])(O)=O.[Na+].NC=1SC(=NN1)Br Chemical compound C([O-])(O)=O.[Na+].NC=1SC(=NN1)Br CRXNCKJXYUXZEM-UHFFFAOYSA-M 0.000 description 1
- ITBNXNYXAQTNMT-UHFFFAOYSA-N C1=CC=C(C=C1)NS(=O)(=O)C2=CN=NS2 Chemical compound C1=CC=C(C=C1)NS(=O)(=O)C2=CN=NS2 ITBNXNYXAQTNMT-UHFFFAOYSA-N 0.000 description 1
- ACWGFPLVTZWZEX-UHFFFAOYSA-N CC(C)CNN1NC=CS1 Chemical compound CC(C)CNN1NC=CS1 ACWGFPLVTZWZEX-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- VFXSMCDSBOOZJH-UHFFFAOYSA-N CN(CC1=CC=CC=C1)C(C1=CN=NS1)=O Chemical compound CN(CC1=CC=CC=C1)C(C1=CN=NS1)=O VFXSMCDSBOOZJH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- MZJABLICBQKTDI-UHFFFAOYSA-N FC1=CC=C(OC2=NN3C(S2)=NC=C3)C=C1.FC1=CC=C(OC3=NN2C(S3)=NC=C2I)C=C1 Chemical compound FC1=CC=C(OC2=NN3C(S2)=NC=C3)C=C1.FC1=CC=C(OC3=NN2C(S3)=NC=C2I)C=C1 MZJABLICBQKTDI-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101710160287 Heterochromatin protein 1 Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- SXHACMXRKHXZTR-UHFFFAOYSA-N N-(cyclopropylmethyl)-5-(1-methylpyrazol-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1(CC1)CNC1=NN2C(S1)=NC=C2C=1C=NN(C=1)C SXHACMXRKHXZTR-UHFFFAOYSA-N 0.000 description 1
- WKLJVUARYZVPGW-UHFFFAOYSA-N N-[4-[2-(4-fluoroanilino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide N-(4-fluorophenyl)-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC1=CC=C(C=C1)NC1=NN2C(S1)=NC=C2I.FC2=CC=C(C=C2)NC2=NN1C(S2)=NC=C1C1=CC=C(C=C1)NC(C)=O WKLJVUARYZVPGW-UHFFFAOYSA-N 0.000 description 1
- VINNVKQLFIJQNR-UHFFFAOYSA-N N-benzyl-2-(dimethylamino)-N-methylimidazo[2,1-b][1,3,4]thiadiazole-5-carboxamide 2-(dimethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde Chemical compound CN(C1=NN2C(S1)=NC=C2C=O)C.C(C2=CC=CC=C2)N(C(=O)C2=CN=C1SC(=NN12)N(C)C)C VINNVKQLFIJQNR-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 description 1
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- DJIOHRPAVFWMHE-UHFFFAOYSA-N [4-(2-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CN=C2N1N=C(C=1C=CC=CC=1)S2 DJIOHRPAVFWMHE-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical group NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 101150069072 cdc25 gene Proteins 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- MVHJGIFBMMWKED-UHFFFAOYSA-L copper triphenylphosphane dibromide Chemical compound [Cu+2].[Br-].[Br-].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MVHJGIFBMMWKED-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- JETOYKBMVCNBTF-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(N)=NN21 JETOYKBMVCNBTF-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- RISHBUAIGFJJAA-UHFFFAOYSA-N n,n-dimethyl-3-[2-(2-methylpropylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC(C(=O)N(C)C)=C1 RISHBUAIGFJJAA-UHFFFAOYSA-N 0.000 description 1
- AMBWKFHFOVGMSZ-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-(3-chloro-4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(F)=CC=C1C1=CN=C2N1N=C(NCC=1C=C3OCOC3=CC=1)S2 AMBWKFHFOVGMSZ-UHFFFAOYSA-N 0.000 description 1
- XTLUNENWXYJDSO-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C2N1N=C(NCC=1C=C3OCOC3=CC=1)S2 XTLUNENWXYJDSO-UHFFFAOYSA-N 0.000 description 1
- NOXRBJSRUMFIPH-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1C=C2OCOC2=CC=1CNC(SC1=NC=2)=NN1C=2C1=CC=CN=C1 NOXRBJSRUMFIPH-UHFFFAOYSA-N 0.000 description 1
- ZFSPSYARQVWKDR-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-[2-(oxan-4-ylmethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1C1=CN=C2N1N=C(NCC1CCOCC1)S2 ZFSPSYARQVWKDR-UHFFFAOYSA-N 0.000 description 1
- MOJYWKGKUILWBJ-UHFFFAOYSA-N n-(2-methoxyethyl)-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=C(OC)N=C1 MOJYWKGKUILWBJ-UHFFFAOYSA-N 0.000 description 1
- CCDJMYZAXVOYEP-UHFFFAOYSA-N n-(2-methoxyethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(OC(F)(F)F)=C1 CCDJMYZAXVOYEP-UHFFFAOYSA-N 0.000 description 1
- MOQLAMZTSGAFDX-UHFFFAOYSA-N n-(2-methoxyethyl)-5-thiophen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CS1 MOQLAMZTSGAFDX-UHFFFAOYSA-N 0.000 description 1
- PSPGMZAEHRFFAB-UHFFFAOYSA-N n-(2-methoxyethyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C=1C=CSC=1 PSPGMZAEHRFFAB-UHFFFAOYSA-N 0.000 description 1
- KYHMXRQTDLZCKP-UHFFFAOYSA-N n-(2-methoxyethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(NCCOC)=NN21 KYHMXRQTDLZCKP-UHFFFAOYSA-N 0.000 description 1
- KZMFSZWGTPNRCG-UHFFFAOYSA-N n-(2-methylpropyl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CC=C1 KZMFSZWGTPNRCG-UHFFFAOYSA-N 0.000 description 1
- HXHXCSIFDPDCIQ-UHFFFAOYSA-N n-(2-methylpropyl)-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=CN=C1 HXHXCSIFDPDCIQ-UHFFFAOYSA-N 0.000 description 1
- BWXFREREELCTCS-UHFFFAOYSA-N n-(2-methylpropyl)-5-pyridin-4-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C1=CC=NC=C1 BWXFREREELCTCS-UHFFFAOYSA-N 0.000 description 1
- WWUWXBRWYGCIKH-UHFFFAOYSA-N n-(2-methylpropyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC(C)C)=NN2C=1C=1C=CSC=1 WWUWXBRWYGCIKH-UHFFFAOYSA-N 0.000 description 1
- UCQMPXFLXARWBI-UHFFFAOYSA-N n-(2-methylpropyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CN=C2SC(NCC(C)C)=NN21 UCQMPXFLXARWBI-UHFFFAOYSA-N 0.000 description 1
- PSKXGZZKPQYUIK-UHFFFAOYSA-N n-(2-piperidin-1-ylethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC(C=2N3N=C(NCCN4CCCCC4)SC3=NC=2)=C1 PSKXGZZKPQYUIK-UHFFFAOYSA-N 0.000 description 1
- QFYJDYJRRPLHJZ-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C3=CSC=C3)=CN=C2SC=1NCCC1=CC=CC=N1 QFYJDYJRRPLHJZ-UHFFFAOYSA-N 0.000 description 1
- AGEPOTAQOQLOMC-UHFFFAOYSA-N n-(3-acetylphenyl)-2-(cyclopropylmethylamino)imidazo[2,1-b][1,3,4]thiadiazole-5-carboxamide Chemical compound CC(=O)C1=CC=CC(NC(=O)C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 AGEPOTAQOQLOMC-UHFFFAOYSA-N 0.000 description 1
- PBJXLEWFHAJFRQ-UHFFFAOYSA-N n-(3-fluorophenyl)-2-phenoxyimidazo[2,1-b][1,3,4]thiadiazol-5-amine Chemical compound FC1=CC=CC(NC=2N3N=C(OC=4C=CC=CC=4)SC3=NC=2)=C1 PBJXLEWFHAJFRQ-UHFFFAOYSA-N 0.000 description 1
- VHYGTQCSYAQOLI-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-5-[4-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN=C2N1N=C(NCCCN1C=NC=C1)S2 VHYGTQCSYAQOLI-UHFFFAOYSA-N 0.000 description 1
- WREPUICJGAAQOR-UHFFFAOYSA-N n-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1NC(S1)=NN2C1=NC=C2 WREPUICJGAAQOR-UHFFFAOYSA-N 0.000 description 1
- XMMMDVYPWITFTE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(1h-indol-5-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(C=3C=C4C=CNC4=CC=3)=CN=C2SC=1NCC1CC1 XMMMDVYPWITFTE-UHFFFAOYSA-N 0.000 description 1
- CGWJLHITDDYAMZ-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(3,4-dimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 CGWJLHITDDYAMZ-UHFFFAOYSA-N 0.000 description 1
- QZRKHFUOAFSPNE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 QZRKHFUOAFSPNE-UHFFFAOYSA-N 0.000 description 1
- PBYJYCODVPYEFO-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 PBYJYCODVPYEFO-UHFFFAOYSA-N 0.000 description 1
- FOIROZXHNLZCFE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[3-(trifluoromethoxy)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC(C=2N3N=C(NCC4CC4)SC3=NC=2)=C1 FOIROZXHNLZCFE-UHFFFAOYSA-N 0.000 description 1
- AYHVFLVXXWZGCF-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-[4-(trifluoromethyl)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN=C2N1N=C(NCC1CC1)S2 AYHVFLVXXWZGCF-UHFFFAOYSA-N 0.000 description 1
- FWAULMRSPJPDBS-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound N=1N2C(I)=CN=C2SC=1NCC1CC1 FWAULMRSPJPDBS-UHFFFAOYSA-N 0.000 description 1
- HUKXSRTYEMREOD-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-morpholin-4-ylsulfonylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1N=C2SC(NCC3CC3)=NN2C=1S(=O)(=O)N1CCOCC1 HUKXSRTYEMREOD-UHFFFAOYSA-N 0.000 description 1
- UEZDOPQKHRFCEN-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CC1CNC(SC1=NC=2)=NN1C=2C1=CC=CN=C1 UEZDOPQKHRFCEN-UHFFFAOYSA-N 0.000 description 1
- LIGZLOYUNBSQQE-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-pyridin-4-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CC1CNC(SC1=NC=2)=NN1C=2C1=CC=NC=C1 LIGZLOYUNBSQQE-UHFFFAOYSA-N 0.000 description 1
- ICAWVKLDJVTFAB-UHFFFAOYSA-N n-(cyclopropylmethyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CC1CNC(SC1=NC=2)=NN1C=2C=1C=CSC=1 ICAWVKLDJVTFAB-UHFFFAOYSA-N 0.000 description 1
- FNPLKMSLRQHUAT-UHFFFAOYSA-N n-(furan-2-ylmethyl)-5-(1-methylpyrazol-4-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NN(C)C=C1C1=CN=C2N1N=C(NCC=1OC=CC=1)S2 FNPLKMSLRQHUAT-UHFFFAOYSA-N 0.000 description 1
- OCYRPJAZZHAFAP-UHFFFAOYSA-N n-(furan-2-ylmethyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1C=COC=1CNC(SC1=NC=2)=NN1C=2C=1C=CSC=1 OCYRPJAZZHAFAP-UHFFFAOYSA-N 0.000 description 1
- LWQHPDYYKSJORY-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-5-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1COCCC1CNC(SC1=NC=2)=NN1C=2C1=CC=CC=C1 LWQHPDYYKSJORY-UHFFFAOYSA-N 0.000 description 1
- RKXXOIMICBPBID-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-5-thiophen-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1COCCC1CNC(SC1=NC=2)=NN1C=2C=1C=CSC=1 RKXXOIMICBPBID-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- JJCKCEFEVHIGGC-UHFFFAOYSA-N n-[(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl]-3,4-dimethoxyaniline Chemical compound C1=C(OC)C(OC)=CC=C1NCC1=CN=C2N1N=C(Br)S2 JJCKCEFEVHIGGC-UHFFFAOYSA-N 0.000 description 1
- SYOQEIOUWRVTOT-UHFFFAOYSA-N n-[(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl]-3-chloro-4-fluoroaniline Chemical compound C1=C(Cl)C(F)=CC=C1NCC1=CN=C2N1N=C(Br)S2 SYOQEIOUWRVTOT-UHFFFAOYSA-N 0.000 description 1
- QGLTZRAQVOHETI-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CC1=CC=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CN=C1 QGLTZRAQVOHETI-UHFFFAOYSA-N 0.000 description 1
- XZEXRSDLYCSRJD-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(S1)=NN2C1=NC=C2 XZEXRSDLYCSRJD-UHFFFAOYSA-N 0.000 description 1
- MQMLUZIRGTUZFG-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(1h-indol-5-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(NC=C2)C2=C1 MQMLUZIRGTUZFG-UHFFFAOYSA-N 0.000 description 1
- YINAHDDRPAMQBB-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC=4C=CC(F)=CC=4)SC3=NC=2)=C1 YINAHDDRPAMQBB-UHFFFAOYSA-N 0.000 description 1
- HZHHADDTOWKLHE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC(F)=CC=1)S2 HZHHADDTOWKLHE-UHFFFAOYSA-N 0.000 description 1
- BYMPEVBUHPBMPL-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-morpholin-4-ylsulfonylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2S(=O)(=O)N1CCOCC1 BYMPEVBUHPBMPL-UHFFFAOYSA-N 0.000 description 1
- NEHGQYYUYZAZGD-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-naphthalen-2-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=C(C=CC=C2)C2=C1 NEHGQYYUYZAZGD-UHFFFAOYSA-N 0.000 description 1
- GVLLMCJMUSRNAQ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CN=C1 GVLLMCJMUSRNAQ-UHFFFAOYSA-N 0.000 description 1
- YPLRAXYKTPWBQM-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-pyridin-4-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=NC=C1 YPLRAXYKTPWBQM-UHFFFAOYSA-N 0.000 description 1
- WKTUYYCWVFVSRA-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC(S1)=NN2C1=NC=C2 WKTUYYCWVFVSRA-UHFFFAOYSA-N 0.000 description 1
- GLAFFGORWXRWQA-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-5-(2-phenylethynyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C#CC1=CC=CC=C1 GLAFFGORWXRWQA-UHFFFAOYSA-N 0.000 description 1
- HNRPGAGFXZPTGI-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-5-pyridin-4-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=CC(OC)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=NC=C1 HNRPGAGFXZPTGI-UHFFFAOYSA-N 0.000 description 1
- VDVXHGKYOAPCFH-UHFFFAOYSA-N n-[2-[(3,4-dichlorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]ethanesulfonamide Chemical compound N=1N2C(NS(=O)(=O)CC)=CN=C2SC=1NCC1=CC=C(Cl)C(Cl)=C1 VDVXHGKYOAPCFH-UHFFFAOYSA-N 0.000 description 1
- JBKUQDZWQHTQLK-UHFFFAOYSA-N n-[3-[2-(2-methoxyethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C=1N=C2SC(NCCOC)=NN2C=1C1=CC=CC(NC(C)=O)=C1 JBKUQDZWQHTQLK-UHFFFAOYSA-N 0.000 description 1
- XRMZQRNAQVLNSE-UHFFFAOYSA-N n-[3-[2-(2-pyridin-2-ylethylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCCC=4N=CC=CC=4)SC3=NC=2)=C1 XRMZQRNAQVLNSE-UHFFFAOYSA-N 0.000 description 1
- ALTWVVSEECZRSY-UHFFFAOYSA-N n-[3-[2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N3N=C(NCC=4C=CC(F)=CC=4)SC3=NC=2)=C1 ALTWVVSEECZRSY-UHFFFAOYSA-N 0.000 description 1
- ONABRYSWQOPWAH-UHFFFAOYSA-N n-[3-[2-[[4-(dimethylamino)phenyl]methylamino]imidazo[2,1-b][1,3,4]thiadiazol-5-yl]phenyl]acetamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(S1)=NN2C1=NC=C2C1=CC=CC(NC(C)=O)=C1 ONABRYSWQOPWAH-UHFFFAOYSA-N 0.000 description 1
- JTGCSPVFAXPELK-UHFFFAOYSA-N n-[5-(3-acetylphenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]propanamide Chemical compound C=1N=C2SC(NC(=O)CC)=NN2C=1C1=CC=CC(C(C)=O)=C1 JTGCSPVFAXPELK-UHFFFAOYSA-N 0.000 description 1
- IOPGJDSPAOHSBD-UHFFFAOYSA-N n-benzyl-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NCC=4C=CC=CC=4)SC3=NC=2)=C1 IOPGJDSPAOHSBD-UHFFFAOYSA-N 0.000 description 1
- MJEOVHVSIHUUME-UHFFFAOYSA-N n-benzyl-5-(6-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CN=C2N1N=C(NCC=1C=CC=CC=1)S2 MJEOVHVSIHUUME-UHFFFAOYSA-N 0.000 description 1
- IKELEJBGZYYKPN-UHFFFAOYSA-N n-benzyl-5-[3-(dimethylamino)phenyl]imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound CN(C)C1=CC=CC(C=2N3N=C(NCC=4C=CC=CC=4)SC3=NC=2)=C1 IKELEJBGZYYKPN-UHFFFAOYSA-N 0.000 description 1
- FSNMUERJJCKLRC-UHFFFAOYSA-N n-benzyl-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1C=CC=CC=1CNC(SC1=NC=2)=NN1C=2C1=CC=CN=C1 FSNMUERJJCKLRC-UHFFFAOYSA-N 0.000 description 1
- JSXJUMMDTQNYLW-UHFFFAOYSA-N n-benzyl-5-pyridin-4-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C=1C=CC=CC=1CNC(SC1=NC=2)=NN1C=2C1=CC=NC=C1 JSXJUMMDTQNYLW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QMWXEPORZMVMOB-UHFFFAOYSA-N n-cyclohexyl-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound COC1=CN=CC(C=2N3N=C(NC4CCCCC4)SC3=NC=2)=C1 QMWXEPORZMVMOB-UHFFFAOYSA-N 0.000 description 1
- GFBSMMTYURIXOJ-UHFFFAOYSA-N n-cyclohexyl-5-pyridin-3-ylimidazo[2,1-b][1,3,4]thiadiazol-2-amine Chemical compound C1CCCCC1NC(S1)=NN2C1=NC=C2C1=CC=CN=C1 GFBSMMTYURIXOJ-UHFFFAOYSA-N 0.000 description 1
- BDFZYAAZZOPRMG-UHFFFAOYSA-N n-ethyl-2-[(4-fluorophenyl)methylamino]imidazo[2,1-b][1,3,4]thiadiazole-5-sulfonamide Chemical compound N=1N2C(S(=O)(=O)NCC)=CN=C2SC=1NCC1=CC=C(F)C=C1 BDFZYAAZZOPRMG-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07381066.5 | 2007-09-27 | ||
| EP07381066 | 2007-09-27 | ||
| PCT/GB2008/003287 WO2009040552A2 (en) | 2007-09-27 | 2008-09-29 | Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540508A JP2010540508A (ja) | 2010-12-24 |
| JP2010540508A5 JP2010540508A5 (index.php) | 2011-11-17 |
| JP5410431B2 true JP5410431B2 (ja) | 2014-02-05 |
Family
ID=39092755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526362A Expired - Fee Related JP5410431B2 (ja) | 2007-09-27 | 2008-09-29 | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8563550B2 (index.php) |
| EP (1) | EP2193133B1 (index.php) |
| JP (1) | JP5410431B2 (index.php) |
| CN (1) | CN101878219B (index.php) |
| CY (1) | CY1116882T1 (index.php) |
| DK (1) | DK2193133T3 (index.php) |
| ES (1) | ES2548768T3 (index.php) |
| HR (1) | HRP20151128T1 (index.php) |
| HU (1) | HUE025976T2 (index.php) |
| PL (1) | PL2193133T3 (index.php) |
| PT (1) | PT2193133E (index.php) |
| SI (1) | SI2193133T1 (index.php) |
| WO (1) | WO2009040552A2 (index.php) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN105012953B (zh) | 2005-07-25 | 2018-06-22 | 阿普泰沃研发有限责任公司 | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 |
| KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
| US8563550B2 (en) | 2007-09-27 | 2013-10-22 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazolothiadiazoles for use as protein kinase inhibitors |
| MX340204B (es) | 2008-04-11 | 2016-06-30 | Emergent Product Dev Seattle | Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo. |
| AU2009275544B2 (en) * | 2008-07-29 | 2013-09-12 | Merck Patent Gmbh | Imidazothiadiazoles derivatives |
| DK2414369T3 (en) * | 2009-04-02 | 2015-09-21 | Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii | Imidazo [2,1-b] [1,3,4] thiadiazole derivatives |
| FR2945289A1 (fr) * | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| CA2775204A1 (en) | 2009-09-24 | 2011-03-31 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| SG183361A1 (en) | 2010-02-18 | 2012-09-27 | Ct Nac Investigaciones Oncologicas Cnio | Triazolo [4, 5 - b] pyridin derivatives |
| WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
| EP4438734A3 (en) | 2010-06-14 | 2024-12-25 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2012020217A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020227A1 (en) | 2010-08-11 | 2012-02-16 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| EP2710018B8 (en) | 2011-05-19 | 2022-02-23 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| EP2671885A1 (en) * | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| EP2682395A1 (en) | 2012-07-04 | 2014-01-08 | Laboratorios Del. Dr. Esteve, S.A. | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments |
| BR112015001201B1 (pt) * | 2012-07-18 | 2022-02-22 | University Of Notre Dame Du Lac | Compostos anti-infecciosos 5,5-heteroaromáticos e composição |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| SI3386511T1 (sl) | 2015-12-10 | 2021-09-30 | Ptc Therapeutics, Inc. | Postopki za zdravljenje Huntingtonove bolezni |
| US20190119300A1 (en) * | 2016-04-18 | 2019-04-25 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
| BR112019025740A2 (pt) | 2017-06-05 | 2020-06-23 | Ptc Therapeutics, Inc. | Compostos para tratar a doença de huntington |
| EP3645121B8 (en) | 2017-06-28 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| EP3774744B1 (en) | 2018-03-27 | 2025-02-12 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| BR112020026545A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington |
| SG11202012869SA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heteroaryl compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| CA3104054A1 (en) * | 2018-08-21 | 2020-02-27 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic heteroaromatic ring derivative |
| BR112022007404A2 (pt) * | 2019-10-21 | 2022-07-05 | Novartis Ag | Compostos e composições para o tratamento de doenças parasíticas |
| EP4442692A4 (en) * | 2021-11-29 | 2025-10-01 | Ocean Univ China | IMIDAZOTHIAZOLE DERIVATIVE, PROCESS FOR ITS PREPARATION AND USE |
| CN114195736B (zh) * | 2021-12-30 | 2023-08-04 | 浙江闰土染料有限公司 | 2-氨基-5-溴-1,3,4-噻二唑的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1464259A (en) * | 1975-10-03 | 1977-02-09 | Pfizer Ltd | Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents |
| US4444770A (en) | 1980-05-29 | 1984-04-24 | Bayer Aktiengesellschaft | New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use |
| DE3208437A1 (de) | 1982-03-09 | 1983-09-15 | Bayer Ag, 5090 Leverkusen | Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln |
| IT1269176B (it) | 1994-01-11 | 1997-03-21 | Isagro Srl | Eterobicicli ad attivita' fungicida |
| WO1997011075A1 (en) | 1995-09-22 | 1997-03-27 | Takeda Chemical Industries, Ltd. | Triazole compounds, their production and use |
| MXPA03001189A (es) | 2000-08-09 | 2004-05-14 | Agouron Pharma | Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas. |
| CA2364985A1 (en) * | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
| KR101075812B1 (ko) | 2002-12-18 | 2011-10-25 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서의 트리아졸로피리다진 |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US20060135571A1 (en) * | 2003-06-13 | 2006-06-22 | Jaquith James B | Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones |
| US20070112043A1 (en) | 2003-06-13 | 2007-05-17 | Jaquith James B | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof |
| WO2006128693A2 (en) * | 2005-06-01 | 2006-12-07 | Ucb Pharma, S.A. | 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system |
| US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| EP1963329B1 (en) | 2005-11-30 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| BRPI0710133A2 (pt) | 2006-04-13 | 2012-10-30 | Aegera Therapeutics Inc | uso de compostos de imidazo[2,1-b]-1,3,4-tiadiazol-2-sulfonamida para tratar dor neuropática |
| US20070267288A1 (en) | 2006-05-21 | 2007-11-22 | Steven Allen Carlson | Systems and methods for hydrogen storage and generation |
| CN101037445A (zh) * | 2007-04-14 | 2007-09-19 | 西北师范大学 | 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法 |
| JP2010526120A (ja) | 2007-05-09 | 2010-07-29 | ノバルティス アーゲー | Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン |
| EP2162132A4 (en) * | 2007-05-21 | 2013-01-16 | Sgx Pharmaceuticals Inc | Heterocyclic kinase modulators |
| US8563550B2 (en) | 2007-09-27 | 2013-10-22 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazolothiadiazoles for use as protein kinase inhibitors |
| AU2009275544B2 (en) | 2008-07-29 | 2013-09-12 | Merck Patent Gmbh | Imidazothiadiazoles derivatives |
-
2008
- 2008-09-29 US US12/679,514 patent/US8563550B2/en not_active Expired - Fee Related
- 2008-09-29 WO PCT/GB2008/003287 patent/WO2009040552A2/en not_active Ceased
- 2008-09-29 CN CN200880118104.5A patent/CN101878219B/zh not_active Expired - Fee Related
- 2008-09-29 ES ES08806437.3T patent/ES2548768T3/es active Active
- 2008-09-29 PT PT88064373T patent/PT2193133E/pt unknown
- 2008-09-29 DK DK08806437.3T patent/DK2193133T3/en active
- 2008-09-29 JP JP2010526362A patent/JP5410431B2/ja not_active Expired - Fee Related
- 2008-09-29 SI SI200831527T patent/SI2193133T1/sl unknown
- 2008-09-29 HR HRP20151128TT patent/HRP20151128T1/hr unknown
- 2008-09-29 HU HUE08806437A patent/HUE025976T2/en unknown
- 2008-09-29 EP EP08806437.3A patent/EP2193133B1/en active Active
- 2008-09-29 PL PL08806437T patent/PL2193133T3/pl unknown
-
2015
- 2015-11-03 CY CY20151100982T patent/CY1116882T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8563550B2 (en) | 2013-10-22 |
| EP2193133B1 (en) | 2015-08-19 |
| DK2193133T3 (en) | 2015-10-05 |
| EP2193133A2 (en) | 2010-06-09 |
| HUE025976T2 (en) | 2016-05-30 |
| PT2193133E (pt) | 2015-10-22 |
| SI2193133T1 (sl) | 2015-12-31 |
| HRP20151128T1 (hr) | 2015-11-20 |
| WO2009040552A2 (en) | 2009-04-02 |
| PL2193133T3 (pl) | 2016-01-29 |
| CN101878219A (zh) | 2010-11-03 |
| CY1116882T1 (el) | 2017-04-05 |
| US20110190289A1 (en) | 2011-08-04 |
| CN101878219B (zh) | 2014-04-02 |
| JP2010540508A (ja) | 2010-12-24 |
| WO2009040552A3 (en) | 2009-05-22 |
| ES2548768T3 (es) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5410431B2 (ja) | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 | |
| AU2010231162B2 (en) | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives | |
| KR101792837B1 (ko) | 키나아제 억제제로서 사용을 위한 이미다조피라진 | |
| US20110046127A1 (en) | Imidazopyridazines for Use as Protein Kinase Inhibitors | |
| ES2649144T3 (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 | |
| JP5913126B2 (ja) | キナーゼ阻害剤としての使用のための三環式化合物 | |
| KR20100015353A (ko) | Ｊａｋ３ 억제제로서의 피롤로피리미딘 유도체 | |
| US20130065883A1 (en) | Triazolo [4, 5- B] Pyridin Derivatives | |
| WO2012020215A1 (en) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors | |
| WO2012098387A1 (en) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors | |
| WO2012020217A1 (en) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors | |
| HK1166979B (en) | Imidazo [2, 1-b] [1, 3, 4] thiadiazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130918 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131015 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131106 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5410431 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |